Overhaul sees Glaxo slash 350 analysis and improvement roles throughout the US and UK

GSK is axing around 350 research and development jobs across the US and UK as part of an ongoing overhaul of the division.

It is understood around 50 UK jobs have so far been cut in the drugs giant’s main UK R&D hub in Stevenage, although there are set to be more losses in Britain and at its US site amid changes across the wider division.

The group announced five years ago a move to merge its vaccines and speciality medicines operations, alongside spinning off its consumer healthcare arm, which listed as Haleon in 2022.

The firm has since been cutting out duplicated roles as part of the R&D changes.

GSK – which employs around 12,000 workers in its global R&D operations – did not say how many UK jobs in total would go in the latest round of cuts, which will see up to 350 roles lost across its UK and American sites. 

It has more than 2,500 employees at its Stevenage R&D site.

Shake-up: GSK – which employs around 12,000 workers in its global R&D operations – said it is to cut some 350 jobs in the division

The firm insisted it is continuing to increase R&D investment in the UK, having spent more than £1.5billion last year.

A GSK spokesman said its R&D investment ‘has risen by almost 90 per cent over recent years – to £6.4billion in 2024’.

‘And we expect it to increase further as we focus on delivering our pipeline of new medicines,’ the spokesman said.

The firm unveils its annual results on Wednesday – the first set of figures since Luke Miels took over as chief executive on January 1.